Navigation Links
Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
Date:1/8/2010

FRAZER, Pa., Jan. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that effective February 5, 2010, Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical Operations, will resign his position with the company to pursue other longstanding interests. During his tenure, Mr. Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue. The company will announce plans for its leadership and the commercial organization in the near future. Additionally, the global commercial leadership team, Alain Aragues, President of Cephalon Europe, Paul Li, Senior Vice President of International Pharmaceutical Operations, and Robert Repella, Senior Vice President of U.S. Pharmaceutical Operations, will continue to lead their respective organizations.

"Bob Roche made a tremendous contribution to the worldwide commercial success of Cephalon. On behalf of the board of directors and executive team, I want to express my appreciation for his 15 years of excellent service and leadership in establishing Cephalon as one of the leading biopharmaceutical companies in the world," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Bob built strong global sales and marketing organizations and we remain enthusiastic about our growth opportunities and the future of our company."

Since 1995, Mr. Roche has led the worldwide commercial organization which now has more than 30 products. He was promoted to Senior Vice President, Worldwide Pharmaceutical Operations, in 2000, and named an Executive Vice President in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham's central nervous system and gastrointestinal products busine
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
3. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
4. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
10. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
11. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, ... and launched a site-wide wedding gown promotion. , ... in a more unexpected way, the collection should be a ... the global market, and they are available with custom service. ... at discounted prices, up to 75% off; most of them ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... WASHINGTON, D.C.Exemplary work in genetic imaging and therapy have ... & Molecular Biology at Jefferson Medical College of Thomas ... at Jefferson, recognition by his peers as a 2010 ... Science (AAAS). AAAS is honoring Dr. Wickstrom for ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) ... attitude: The most optimistic adolescents may be somewhat less likely ... have found a slight link between optimism and less heavy ... new research, on kids in Australia, doesn,t prove that optimism ...
... a common problem for patients with schizophrenia. The increased tendency ... smoke, but to do so more heavily than the general ... acting as a treatment for some symptoms of schizophrenia. ... those with high and low affinity for nicotine. The low ...
... remains an unresolved issue as to whether interstitial brachytherapy has ... prostate cancer, nor do newer studies provide proof in this ... the Institute for Quality and Efficiency in Health Care (IQWiG) ... newer studies challenged the findings of research already completed in ...
... risk of an ectopic pregnancy because of a lasting effect ... the first time of how chlamydia can increase the risk ... implants outside the womb, in the Fallopian tube. Researchers ... had the sexually transmitted infection were more likely to produce ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) -- The ... on Saturday will likely cause some permanent damage, but experts ... be. However, doctors at University Medical Center in Tucson ... are already encouraged by her ability to follow simple instructions. ...
Cached Medicine News:Health News:Optimism Could Help Kids Keep Depression at Bay 2Health News:Targeting nicotine receptors to treat cognitive impairments in schizophrenia 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:Wounded Congresswoman Responds to Simple Commands 2Health News:Wounded Congresswoman Responds to Simple Commands 3Health News:Wounded Congresswoman Responds to Simple Commands 4
... SYSCAN3® Hospital Test Kit is a multi-well ELISA ... in a standard serology laboratory without the need ... specific antigen preparation from Candida albicans. Our SYSCAN3 ... the presence of antibodies to Candida in the ...
Immunodiffusion tests are used for the detecion of precipitating antibodies (primarily of the IgG and IgA classes) against antigens of C. albicans. The presence of precipitating antibodies indicates ...
... Health Record streamlines patient information management ... A flexible and easily customizable solution, ... financial benefits. HealthMatics EHR organizes communication ... and with outside practitioners. It also ...
... generation of advanced Electronic Medical Records (EMR) ... numerically codified medical vocabularies in the world. ... embedded in MedcomSoft Record, healthcare providers can ... and intuitive point and click system and ...
Medicine Products: